Biopsy material taken from the brain of a patient with CreutzfeldtJakob disease with status spongiosus induced a similar fatal encephalopathy in a chimpanzee 13 months after inoculation.

Previous studies have shown that certain vaccines induce suboptimal responses in people living with HIV (PLWH). However, responses to SARS-CoV-2 vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors.

To determine the influence of expert testimony regarding the general unreliability of eyewitnesses, a twophase study was conducted. In the first phase, 24 community residents served as jurors on four six-person juries. A burglary case was tried in 120 District Court, E1 Paso, Texas. Two juries heard all the evidence including the expert testimony of a psychologist and the other two heard all of the testimony except that of the psychologist. During the second phase, 24 student jurors constituting four six-person juries viewed a videotape of the trial. Two of these juries saw the entire proceeding from the first phase including the expert testimony and the remaining two saw all but the expert testimony. All juries acquitted the defendant; however, those who heard the expert testimony significantly lowered their judgments of the accuracy and reliability of eyewitness identification as well as its overall importance to the trial. Further, those juries that heard the expert testimony spent a significantly longer time discussing eyewitness identification as well as other relevant evidence. No differences between community residents and college student juries were obtained.

The ongoing evolution of SARS-Co-V2 variants to omicron severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. Covid-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The FDA currently allows outpatient CCP for the immunosuppressed. Viral specific antibody levels in CCP can range ten- to hundred-fold between donors unlike the uniform viral specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-delta/pre-omicron donor units obtained before March 2021, 20 post-delta COVID-19/post-vaccination units and one pre-delta/pre-omicron hyperimmunoglobulin preparation for variant specific virus (vaccine-related isolate (WA-1), delta and omicron) neutralization correlated to Euroimmun S1 IgG antibody levels. We observed a 2- to 4-fold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to delta or omicron, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-delta COVID-19/post-vaccination units and the hyperimmunoglobulin effectively neutralized all three variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.